

## **Dr. Noam Pilpel, PhD**

Dr. Pilpel is a drug development professional and executive with more than 10 years of experience in leading R&D in oncology and aging, searching for new medicines for "old" conditions. Dr. Pilpel graduated her PhD *summa cum laude* from the Max Planck Institute for Medical Research in Heidelberg, Germany. She performed two post-doctoral studies at the Sanford-Burnham Institute in San Diego and in the Weizmann Institute of Science.

Dr. Pilpel joined Gilboa Therapeutics as the CTO, leading the pre-clinical development of a breakthrough cell therapy platform targeting solid tumors. Prior to Gilboa Therapeutics, she worked at BiolineRx as an oncology drug development manager, at TargetGene Biotechnologies as the Gene Therapy Lead, and at Augmanity Nano as an R&D Director.